A carregar...
A pilot study of the pan-class I PI3K inhibitor buparlisib in combination with cetuximab in patients with recurrent or metastatic head and neck cancer
BACKGROUND: This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). METHODS: Twelve patients with R/M HNSCC were enrolled. Patients were given oral buparli...
Na minha lista:
| Publicado no: | Head Neck |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8258680/ https://ncbi.nlm.nih.gov/pubmed/31486207 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hed.25910 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|